First US Implant of Implantable Cardioverter-Defibrillator System Allows Full-Body MRI Scans

Introduction and Background

Medtronic has announced the first U.S. insert of the Evera Mri(tm) Surescan^® implantable cardioverter-defibrillator (ICD) System, taking after US Food and Drug Administration (FDA) support for its Investigational Device Exemption (IDE) requisition and vital clinical trial convention. The first gadget was effectively embedded at Marquette General Hospital in Marquette, Mich.

Benefits:
Evera MRI is the first ICD framework to be assessed in the US that allows for magnetic resonance imaging (MRI) scans on any region of the body. The Evera MRI ICD System is presently accessible just for investigational use in the US.

Evera MRI is intended to better fit inside the body, with a molded shape and slight, smooth edges that build patient solace by decreasing skin weight by 30 per cent. The Evera MRI is intended to keep up the same business heading battery life span (up to 11 years) contrasted with past devices.

Evera MRI includes Smartshock(tm) 2.0 - a restrictive stun decrease calculation that is intended to empower the gadget to better separate between perilous and innocuous heart rhythms. OptiVol^® 2.0 Fluid Status Monitoring and complete diagnostics, is also included in the Evera MRI, to identify patients at risk of worsening heart failure and atrial fibrillation.